Rigel Pharmaceuticals, Inc. logo RIGL - Rigel Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 7
SELL 0
STRONG
SELL 0
| PRICE TARGET: $67.00 DETAILS
HIGH: $85.00
LOW: $49.00
MEDIAN: $67.00
CONSENSUS: $67.00
UPSIDE: 43.32%

Stock News

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC), as detected by a U.S. Food and Drug Administration (FDA)-authorized test, with disease progression following at least one line of endocrine therapy.

Aug 13, 2026 04:05 AM • prnewswire.com
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and Rezlidhia trials provide additional growth catalysts.

Aug 05, 2026 06:10 PM • seekingalpha.com
Rigel Reports Second Quarter 2026 Financial Results

Rigel Reports Second Quarter 2026 Financial Results

Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and net income of $17.3 million Expanded commercial portfolio with the in-license of VEPPANU™ (vepdegestrant), with U.S. commercial availability expected in mid-August Advanced R289 development program; Phase 1b study in patients with lower-risk MDS remains on track to complete enrollment in the dose expansion portion and select the recommended Phase 2 dose in the second half of 2026 Updated 2026 Outlook: Total revenues of approximately $285 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $265 million and contract revenues from collaborations of approximately $30 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Aug 04, 2026 12:01 PM • prnewswire.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Jul 07, 2026 04:05 AM • prnewswire.com
Rigel Appoints Board Member Alison L. Hannah, M.D.

Rigel Appoints Board Member Alison L. Hannah, M.D.

Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN FRANCISCO, Calif., July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of Alison L.

Jul 01, 2026 04:05 AM • prnewswire.com
A Look At The Transformation Around Rigel Pharmaceuticals

A Look At The Transformation Around Rigel Pharmaceuticals

Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just over $600 million. RIGL's growth strategy pivots on the Veppanu licensing deal, supplementing strong Tavalisse performance and recent product acquisitions. Q1 revenues rose 10% year-over-year to $58.8 million, but net product revenues rose 26%; management also maintained FY2026 sales guidance of $275–$290 million.

Jun 20, 2026 03:44 AM • seekingalpha.com
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions.

Jun 16, 2026 12:01 PM • prnewswire.com
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO ® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLC Final analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with advanced or metastatic RET-altered thyroid cancer to be presented in a poster session Real-world data further supports the use of REZLIDHIA ®  (olutasidenib) in patients with R/R mIDH1 AML that have received prior venetoclax SOUTH SAN FRANCISCO, Calif., May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment of rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) will be presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, May 29, 2026.

May 21, 2026 01:17 PM • prnewswire.com
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m.

May 14, 2026 04:05 AM • prnewswire.com
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC Pivotal Phase 3 VERITAC-2 clinical trial results showed that vepdegestrant was generally well tolerated and reported mPFS of 5.0 months vs. 2.1 months for fulvestrant, a 2.4-fold improvement, in patients with 2L+ ER+/HER2- mBC with an ESR1 mutation Upon closing of the transaction, VEPPANU will become Rigel's fourth commercial product and its major focus to accelerate revenue growth while leveraging the company's existing infrastructure, contributing meaningfully to the advancement of Rigel's transformational growth strategy Arvinas and Pfizer will receive an upfront $70.0 million and an additional $15.0 million upon the successful completion of certain transition activities, and are eligible for up to $320.0 million in future potential regulatory and commercial milestones  Rigel to host a conference call today at 8:00 a.m.

May 12, 2026 03:00 AM • prnewswire.com

Price Targets